The Allen Institute in Seattle says it is preparing to move from studying how the brain works to developing gene therapy approaches to treat brain disorders. After about two decades of research focused on understanding brain function, the institute’s team is now aiming to apply that knowledge to conditions including Alzheimer’s disease and Parkinson’s disease. NPR reports that the effort reflects a shift toward therapies that target the underlying biology of neurological problems rather than only addressing symptoms. The institute frames its work as a science-driven bet that increased understanding of brain mechanisms is now sufficient to support experimental treatment strategies. The reporting emphasizes the institute’s role as a large, long-term research organization and describes the current stage of planning and preparation for gene therapy research. Details about specific therapy designs, timelines, and clinical testing are not provided in the excerpts, but the sources broadly agree that the institute is beginning a new phase centered on genetic treatments for multiple major brain diseases.